A fentanyl test strip answers one question: whether fentanyl is present in a sample at a detectable level. It cannot say how much is there, whether the drug is potent, whether other dangerous adulterants are present, or whether any amount is safe to take.
That distinction has become more consequential. Federal funds can no longer be used to purchase test strips for distribution to people who use drugs, according to NPR and KFF Health News reporting, a reversal of guidance CDC and SAMHSA issued in 2021.
One boundary on that policy matters and is easy to miss. It does not prohibit federal funds from purchasing test strips for use by law enforcement officers, public health officials, EMTs or other medical professionals, which preserves the government drug-checking programs that publish regular reports on what is circulating in a given area.
The Detection Boundaries
Fentanyl test strips are lateral flow immunoassays, originally designed to detect fentanyl in urine and used off-label on drug samples dissolved in water.
They give a binary result. One line indicates fentanyl present; two lines indicate not detected. They do not quantify, which is the central limitation, because fentanyl overdose is a dose problem. A sample containing a trace and a sample containing a lethal quantity both return the same positive.
Their sensitivity threshold is very low, which creates the opposite issue. Strips can detect incidental contamination from drugs packaged in the same area, producing a positive result that does not reflect a clinically meaningful quantity.
Coverage of fentanyl analogs is uneven. Research screening synthetic opioids across strip brands has found detection blind spots, with some analogs registering and others not.
There is also a sampling problem no strip can solve. Fentanyl distributes unevenly through a powder or pressed pill, so a tested portion may differ substantially from the portion consumed.
The Adulterants Strips Do Not See
The drug supply has changed faster than the tools.
Xylazine, a veterinary sedative that causes severe skin ulcers sometimes leading to amputation, spread widely through the opioid supply, and fentanyl-related overdose deaths involving xylazine rose 276% between January 2019 and June 2022. Xylazine is not an opioid, so naloxone does not reverse its sedation.
Medetomidine, another veterinary sedative substantially more potent than xylazine, and BTMPS, a chemical used in plastics manufacturing, have since appeared across regions.
Benzodiazepines are a further category. In Baltimore last year, three mass overdose incidents in three months in one neighborhood sent dozens of people to hospitals. Follow-up testing found the street drugs contained high levels of N-methylclonazepam, a benzodiazepine. Like opioids, benzodiazepines suppress breathing, and combining them raises overdose risk. They do not respond to opioid overdose reversal drugs. A local harm reduction group subsequently created strips specifically for benzodiazepines.
A fentanyl strip detects none of these. Separate strips exist for some adulterants, and portable spectrometry instruments used at some drug checking sites can identify a broader range of substances, but those are expensive and unavailable at most programs.
The most important negative: no available drug checking technology certifies safety. A negative fentanyl result means fentanyl was not detected in that sample by that strip.
The Evidence on Behavior and Outcomes
The research base is moderate rather than definitive, and it measures behavior more reliably than mortality.
Studies find that people who receive test strips use them at high rates and that positive results are associated with changed behavior. Research summarized by the Pew Charitable Trusts includes a survey of people who inject drugs in North Carolina in which more than four in five used strips before consumption, with those receiving a positive result substantially more likely to report behavior changes. A Rhode Island survey found roughly 45% reported using a smaller amount and about 42% reported using more slowly after a positive result.
Festival settings show a different pattern from community settings. Attendees at a Canadian music festival were more likely to discard substances entirely after a positive result, while participants at a supervised injection site more often proceeded while mitigating risk through slower or smaller dosing.
That difference is informative rather than contradictory. Populations differ in dependence, alternatives available and consequences of discarding a supply.
Evidence linking test strip distribution directly to reduced fatal overdose is thinner and comes from a limited number of studies where strips were part of broader harm reduction efforts, making the independent contribution difficult to isolate.
The Practical Framing
The honest description is that drug checking narrows uncertainty without removing it, and its value depends on what accompanies it.
The administration has said it wants to focus on other approaches. "It is critical that federal funding provided by the American taxpayer goes to effective, common-sense solutions that have been proven to save lives and keep people out of an endless cycle of addiction and moves them into a life of recovery," said Emily Hilliard, an HHS spokesperson, pointing to naloxone distribution.
Harm reduction organizations argue the two are not alternatives. Baltimore's overdose deaths have dropped more than 40% since 2023, which local officials attribute to working on multiple fronts at once. Some organizations affected by earlier funding decisions have described losing grants that supported large volumes of strip distribution, a pattern CBS News documented earlier this year.
Where evidence is strongest is the combination: strips distributed alongside naloxone, education and connection to treatment. Naloxone reverses opioid overdose regardless of what a strip showed, works on fentanyl, and is available without prescription in every state. It is the intervention with the clearest mortality evidence, though it does not reverse xylazine or benzodiazepine effects.
Anyone concerned about substance use for themselves or someone else can reach the SAMHSA National Helpline at 1-800-662-4357, which is free, confidential, and staffed around the clock, and provides referrals to treatment. Whether states, local governments, or private funders fill the distribution gap is unresolved. MedicalDaily has reported on how settlement money is being used for harm reduction in some jurisdictions and on federal investment in community treatment.
Key Questions Answered
What does a fentanyl test strip detect? Whether fentanyl is present in a dissolved sample at a detectable level. It gives a binary result and does not measure quantity or potency.
Why does quantity matter? Fentanyl overdose is a dose problem. A trace amount and a lethal amount both produce the same positive result, so a strip cannot indicate how dangerous a sample is.
What can strips miss? Some fentanyl analogs, due to documented detection blind spots. They also cannot detect xylazine, medetomidine, BTMPS, or benzodiazepines, all of which have appeared in the supply. Fentanyl also distributes unevenly, so a tested portion may differ from what is consumed.
Does a negative result mean a substance is safe? No. It means fentanyl was not detected in that sample by that strip. No available drug checking technology certifies safety.
What does the evidence show about behavior? People who receive strips use them at high rates, and positive results are associated with using smaller amounts, using more slowly, or discarding substances. Evidence linking distribution directly to reduced fatal overdose is thinner.
What exactly changed with federal funding? Federal funds can no longer be used to purchase test strips for distribution to people who use drugs, reversing 2021 guidance. Purchases for use by law enforcement, public health officials, EMTs, and medical professionals are still permitted.
What has the clearest evidence for preventing deaths? Naloxone, which reverses opioid overdose regardless of test results and is available without prescription in every state, though it does not reverse xylazine or benzodiazepines. The SAMHSA National Helpline, 1-800-662-4357, is free and confidential.
